CAR T-cell therapies drive outcomes in lymphoma, myeloma

(American Society of Hematology) For people with certain types of aggressive, refractory blood cancers, treatment options are woefully limited. But three studies being presented today at the 59th American Society of Hematology (ASH) Annual Meeting and Exposition in Atlanta spotlight the emerging role played by chimeric antigen receptor (CAR) T-cell therapies in helping individuals mount a clinical response and, in some cases, achieve durable remission.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news